

#### Adult CIRB - Late Phase Emphasis Meeting Agenda

#### November 20, 2025

#### I Continuing Review

**A031902**, CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer (Version Date 12/10/21)

### **II** Continuing Review

**A042001**, A Randomized Phase II Study Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy plus Blinatumomab Compared to Usual Chemotherapy plus Blinatumomab for Adults with B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma (Version Date 04/03/25)

# **III Continuing Review**

**A051902**, A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas (Version Date 05/27/25)

# **IV** Continuing Review

**A062102**, Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients (Version Date 11/07/24)

# **V** Continuing Review

**A091902**, A Multicenter Phase II Trial of Paclitaxel with and without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma (Version Date 07/29/25)



## **VI** Continuing Review

CCTG-CO32, The NEO-RT Trial: A Phase 3 Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation versus ChemoRadioTherapy for Early Rectal Cancer (Version Date 02/18/25)

#### **VII** Continuing Review

**EA4231**, A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements (HGBCL-DH-BCL2) (Version Date 11/07/25)

### **VIII Continuing Review**

NRG-GY022, Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin (Version Date 09/21/22)

# **IX** Continuing Review

**EA3211**, Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma (Version Date 09/23/25)